2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1757

Review of Effectiveness of an Intensive Rehabilitation Programme in Managing Strength, Pain and Function in 123 Young People with Rheumatological Conditions

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma – ARP

9:00AM-11:00AM: Abstract Number: 1184

Rheumatoid Arthritis Activity Assessment with Cellphone Thermal Camera Imaging Compared to Clinical and Ultrasound Assessments

Imaging Of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1112

Rheumatologists’ Opinions and Use of Telemedicine in the Southwestern U.S

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1607

Risk Factors for Avascular Necrosis in SLE: A Multivariate Model

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1306

Risk Factors for Pain After Total Joint Replacement in Osteoarthritis: Different Pain Measures, Distinct Predictors?

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1283

Risk Factors of Cancer-Associated Inflammatory Myopathies: A Multicenter Study

Muscle Biology, Myositis & Myopathies Poster II

9:00AM-11:00AM: Abstract Number: 1395

Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1339

Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1091

Risk of Preterm Birth by Timing of Lupus Diagnosis Among Women in the Georgia Lupus Registry

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1686

Risk of Vasculitis Associated with Inflammatory Bowel Diseases: Evidence for a Role of TNF-α Blockers

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 1000

RKIP, as an Upstream Regulator of Intracellular Signaling, Exerts Anti-arthritic Effect in Fibroblast-like Synoviocyte and Collagen-induced Arthritis

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1036

RNA Sequencing of PBMCs Reveals Estrogen-Mediated Upregulation of Micro-RNA Processing Machinery

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1595

Role of Aerobic Exercise in Modulating Fatigue in Women with Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1559

Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1525

Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].